Evidence map›Paper›PMID 28503147›Full record

ArticleFrontiers in pharmacology2017

An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling

Tao Su, Jing-Xuan Bai, Ying-Jie Chen, Xin-Ning Wang, Xiu-Qiong Fu, Ting Li, Hui Guo, Pei-Li Zhu, Yue Wang, Zhi-Ling Yu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. miR-7/TGF-Acta pharmaceutica Sinica. B · 2022
    Article
  5. Article
  6. Article
  7. Review
  8. Frontiers in pharmacology · 2021
    Article
  9. Article
  10. Complete Chloroplast Genomes ofPlants (Basel, Switzerland) · 2019
    Article
  11. Article
  12. Frontiers in pharmacology · 2018
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tao SuConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Jing-Xuan BaiConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Ying-Jie ChenConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Xin-Ning WangConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Xiu-Qiong FuConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Ting LiConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Hui GuoConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Pei-Li ZhuConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Yue WangConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Zhi-Ling YuConsun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
Hong Kong Baptist University · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. Signal transducer and activator of transcription 3 (STAT3) signaling is constantly activated in CRC, and has been proposed as a pathogenic factor and a therapeutic target of CRC. Ampelopsis Radix (AR), a traditional Chinese medicinal herb, possesses low toxicity and has long been used clinically for the treatment of cancers including CRC. Some constituents of AR have been reported to exert anti-cancer properties by targeting STAT3. However, the anti-CRC mode and mechanism of action of AR have not been fully elucidated. Here, we investigated the involvement of STAT3 signaling in the anti-CRC effects of AR. Results showed that AR reduced cell viability, induced cell apoptosis, and suppressed cell migration and invasion in human HCT-116 and SW480 CRC cells. Mechanistic studies showed that AR potently suppressed STAT3 and Src phosphorylation, and inhibited STAT3 nuclear localization in cultured CRC cells. AR also downregulated the expression of STAT3 target genes Mcl-1, Bcl-xL, and MMP-2 that are involved in cell survival and mobility. Moreover, the cytotoxic effect of AR was diminished by overexpressing STAT3C, a persistent active variant of STAT3. In conclusion, AR exerted anti-CRC effects

Indexed as

Ampelopsis Radixapoptosiscolorectal cancerinvasionmigrationSTAT3

Identifiers

PMID28503147
PMCPMC5408070
OpenAlexW2610007076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.